Nataša Skočibušić

Mrs. Nataša Skočibušić

orcid
MSc

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2023 in Cancers
Verified
Journal Article
Open access
PDF file
Marin GolčićMarin Golčić
Marin Golčić
LSLuka Simetić
Luka Simetić
DHDavorin Herceg
Davorin Herceg
KBKrešimir Blažičević
Krešimir Blažičević
GJGordana Kenđel Jovanović
Gordana Kenđel Jovanović
SPStjepko Plestina
Stjepko Plestina
Immunotherapy has improved the prognosis of metastatic melanoma patients, although most patients do not achieve a complete response. While specific gut microbiome and dietary habits might influence treatment success, there is a lack of concordance between the studies, potentially due to dichotomizing patients only into responders and non-responders. The aim of this study was to elucidate whether metastatic melanoma patients with complete and sustained response to immunotherapy exhibit differences in gut microbiome composition among themselves, and whether those differences were associated with specific dietary habits. Shotgun metagenomic sequencing revealed that patients who exhibited a complete response after more than 9 months of treatment (late responders) exhibited a significantly higher beta-diversity (p = 0.02), with a higher abundance of Coprococcus comes (LDA 3.548, p = 0.010), Bifidobacterium pseudocatenulatum (LDA 3.392, p = 0.024), and lower abundance of Prevotellaceae (p = 0.04) compared to early responders. Furthermore, late responders exhibited a different diet profile, with a significantly lower intake of proteins and sweets and a higher intake of flavones (p < 0.05). The research showed that metastatic melanoma patients with a complete and sustained response to immunotherapy were a heterogeneous group. Patients with a late complete response exhibited microbiome and dietary habits which were previously associated with an improved response to immunotherapy.

13 November 2023 in Biology and Life Sciences Forum
Verified
Conference Paper
Open access
PDF file
NSNataša Skočibušić
Nataša Skočibušić
Andrej BelančićAndrej Belančić
Andrej Belančić
GJGordana Kenđel Jovanović
Gordana Kenđel Jovanović
Marin GolčićMarin Golčić
Marin Golčić
DHDavorin Herceg
Davorin Herceg
KBKrešimir Blažičević
Krešimir Blažičević
Not all cancer patients respond to immunotherapy, and the variation in response may be attributed to an individual’s microbiome, which is profoundly influenced by dietary habits. Understanding and manipulating the microbiome through dietary interventions offers a potential avenue for enhancing immunotherapy outcomes in cancer patients and may consequently serve as a complementary therapeutic strategy. Bearing in mind the latter, as well as our previous research on the importance of the gut microbiome as a co-denominator for immunotherapy response, we aimed to construct this study protocol on a personalized dietary intervention based on the Mediterranean diet as a complementary strategy to modify the gut microbiome, quality of life and outcomes in patients with metastatic melanoma treated with immunotherapy. The present protocol hypothesis is that remote intervention with the MD will be achievable and will positively affect all the aforementioned parameters. The potential gains of this study protocol and upcoming research extend to enhancing quality-of-life outcomes and the survival rates of patients with metastatic melanoma since it could also result in the reinforcement of the recommendation of nutritional intervention as a crucial component of cancer treatment.

27 February 2026 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
NSNataša Skočibušić
Nataša Skočibušić
IRIgor Rubinić
Igor Rubinić
VVVera Vlahović‐Palčevski
Vera Vlahović‐Palčevski

18 August 2026 in Expert Review of Pharmacoeconomics & Outcomes Research
Verified
Journal Article
Closed access
IRIgor Rubinić
Igor Rubinić
RLRobert Likic
Robert Likic
MPMarina Paladin
Marina Paladin
NSNataša Skočibušić
Nataša Skočibušić
IMInes Mujčin
Ines Mujčin
VVVera Vlahović-Palčevski
Vera Vlahović-Palčevski
1. Immune checkpoint inhibitors (ICIs) have markedly improved clinical outcomes across multiple malignancies [1], including lung cancer, one of the most commonly diagnosed cancer worldwide and the ...

24 October 2025
Verified
Preprint
Open access
NSNataša Skočibušić
Nataša Skočibušić
IRIgor Rubinić
Igor Rubinić
VVVera Vlahović-Palčevski
Vera Vlahović-Palčevski